{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:56:51Z","timestamp":1762300611903},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"14","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>To summarize the pharmacology, efficacy, safety, dosing, administration, and pharmacist perspectives related to operationalization of new and emerging bispecific therapies indicated for the treatment of various cancers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>In recent years, there have been significant advancements in the expansion of immunotherapeutics in the treatment of various malignancies. Bispecific T cell\u2013engaging therapies represent an emerging therapeutic drug class for the treatment of cancer. These therapies are unique antibody constructs that bind simultaneously to 2 targets, a tumor-specific antigen and CD3 on T cells, to elicit an immune response. Recently, several bispecific therapies have been approved, including epcoritamab, glofitamab, mosunetuzumab, tebentafusp, and teclistamab. Epcoritamab and glofitamab have been approved for diffuse large B cell lymphoma, while mosunetuzumab, tebentafusp, and teclistamab have been approved for follicular lymphoma, uveal melanoma, and multiple myeloma, respectively. As a result of their mechanism of action, the approved bispecific therapies have the potential to cause cytokine release syndrome, and, along with this, they all have unique and specific monitoring parameters and operational considerations that require clinician awareness when administering these therapies. Such operational challenges include within-patient dose escalations at therapy initiation, hospitalization for monitoring, and various pharmacological strategies for prophylaxis of cytokine release syndrome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Bispecific therapies have continued to evolve the therapeutic landscape of cancer, primarily in hematological malignancies. Health-system pharmacists have the opportunity to play a key role in the operationalization and management of this new and emerging drug class.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxae050","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T19:15:53Z","timestamp":1708715753000},"page":"574-582","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacist perspectives on emerging T cell\u2013engaging bispecific therapies in cancer therapeutics"],"prefix":"10.1093","volume":"81","author":[{"given":"Donald C","family":"Moore","sequence":"first","affiliation":[{"name":"Atrium Health Levine Cancer Institute , Charlotte, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Digiantonio","sequence":"additional","affiliation":[{"name":"The Ohio State University , Columbus, OH , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn J","family":"Oxencis","sequence":"additional","affiliation":[{"name":"Froedtert and the Medical College of Wisconsin School of Pharmacy , Milwaukee, WI , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate D","family":"Taucher","sequence":"additional","affiliation":[{"name":"Oncology & Infusion Pharmacy Services, Department of Pharmacy, UCHealth , Aurora, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"issue":"1","key":"2024070813011936000_CIT0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1078-0432.CCR-09-2345","article-title":"Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies","volume":"16","author":"Campoli","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2024070813011936000_CIT0002","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/ph14050442","article-title":"The chemistry behind ADCs","volume":"14","author":"Kostova","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"3","key":"2024070813011936000_CIT0003","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/107327481402100308","article-title":"PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy","volume":"21","author":"Dolan","year":"2014","journal-title":"Cancer Control"},{"key":"2024070813011936000_CIT0004","doi-asserted-by":"crossref","first-page":"108873","DOI":"10.1016\/j.clim.2021.108873","article-title":"Immune checkpoint inhibition for the treatment of cancers: an update and critical review of ongoing clinical trials","volume":"232","author":"Akhbariyoon","year":"2021","journal-title":"Clin Immunol"},{"issue":"3","key":"2024070813011936000_CIT0005","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/phar.1900","article-title":"Chimeric antigen receptor T cells in hematologic malignancies","volume":"37","author":"Shank","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"1","key":"2024070813011936000_CIT0006","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2018.09.024","article-title":"American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group survey on chimeric antigen receptor T cell therapy administrative, logistic, and toxicity management practices in the United States","volume":"25","author":"Mahmoudjafari","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2024070813011936000_CIT0007","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jtct.2023.01.021","article-title":"Paving the road for chimeric antigen receptor T cells: American Society for Transplantation and Cellular Therapy 80\/20 Task Force consensus on challenges and solutions to improving efficiency of clinical center certification and maintenance of operations for commercially approved immune effector cell therapies","volume":"29","author":"Nikiforow","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2024070813011936000_CIT0008","author":"Blincyto (blinatumomab)","year":"2022"},{"key":"2024070813011936000_CIT0009","author":"Epkinly (epcoritamab)","year":"2023"},{"key":"2024070813011936000_CIT0010","author":"Columvi (glofitamab)","year":"2023"},{"key":"2024070813011936000_CIT0011","author":"Lunsumio (mosunetuzumab)","year":"2022"},{"key":"2024070813011936000_CIT0012","author":"Kimmtrak (tebentafusp)","year":"2022"},{"key":"2024070813011936000_CIT0013","author":"Tecvayli (teclistamab)","year":"2022"},{"key":"2024070813011936000_CIT0014","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2147\/DDDT.S151282","article-title":"Bispecific antibodies: design, therapy, perspectives","volume":"12","author":"Sedykh","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"suppl 3","key":"2024070813011936000_CIT0015","first-page":"S21","article-title":"Clinical pharmacology of bispecific antibody constructs","volume":"55","author":"Rathi","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"2024070813011936000_CIT0016","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.ijbiomac.2020.11.058","article-title":"Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: recent advances and clinical trials","volume":"167","author":"Hosseini","year":"2021","journal-title":"Int J Biol Macromol"},{"issue":"8","key":"2024070813011936000_CIT0017","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2024070813011936000_CIT0018","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ctrv.2018.04.002","article-title":"Bispecific antibodies in haematological malignancies","volume":"65","author":"Viardot","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"2024070813011936000_CIT0019","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"24","key":"2024070813011936000_CIT0020","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"2024070813011936000_CIT0021","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"13","key":"2024070813011936000_CIT0022","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"2024070813011936000_CIT0023","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxae050\/56992008\/zxae050.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/14\/574\/58469507\/zxae050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/14\/574\/58469507\/zxae050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T13:23:13Z","timestamp":1720444993000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/81\/14\/574\/7613328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":23,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2024,2,23]]},"published-print":{"date-parts":[[2024,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxae050","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7,15]]},"published":{"date-parts":[[2024,2,23]]}}}